glp-1 receptor agonist type 1 diabetes trial liraglutide glp-1_analogs [TUSOM Clinical efficacy results from clinical

All-cause and cardiovascular-related mortality in CKD patients with and without heart failure: a population-based cohort study in Kaiser Permanente Southern California

Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

doi: 10.1172/jci.insight.133429 146 SalamehTSRheaEMTalbotKBanksWA

WHO in September added GLP-1 drugs as a diabetes treatment to its list of essential medicines, but stopped short of adding them for obesity alone

Phase II Trials In a phase II double-blind, randomized, placebo-controlled trial, Jastreboff et al